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Introduction
Primary aldosteronism (PA) displays a prevalence of around 5–10 % 
in patients with hypertension increasing up to 20 % in patients with 
treatment-resistant hypertension [1–3]. Patients with PA have an 
elevated risk of cerebrovascular and cardiovascular events relative 
to patients with hypertension with matched cardiovascular risk pro-
files [4–6]. Different subtypes of PA have been defined which affect 
one or both adrenal glands. The main subtypes are a unilateral al-
dosterone-producing adenoma (APA) or bilateral adrenal hyper-
plasia (BAH, also called idiopathic hyperaldosteronism). Other spo-
radic forms include unilateral adrenal hyperplasia and the very rare 
occurrences of aldosterone-producing carcinoma. Hereditary 
forms of familial hyperaldosteronism are rare and the genetic basis 
of the 4 described forms of familial hyperaldosteronism (FH types 
I–IV) has been identified [7, 8]. A number of somatic mutations, 
mainly in ion channels and ATPases, have been reported which are 
likely to drive the aldosterone excess in the majority of APAs. In-
creasing interest in autoantibodies led to studies reporting a po-
tential role for autoantibodies against the G-protein-coupled re-
ceptor (GPCR) angiotensin II type 1 receptor in PA.
G-Protein-Coupled Receptors
The largest superfamily of receptors in the human genome are 
GPCRs that are located in the plasma membrane of nearly all cell 
types [9]. The research of Kobilka and Lefkowitz about the molec-
ular structure and function of GPCRs, especially β2-adrenergic 
G-protein-coupled receptors, was rewarded in 2012 by the Nobel 
prize in chemistry [10]. GPCRs are responsible for signal transduc-
tion to regulate numerous essential functions by mediating extra-
cellular signals from hormones, neurotransmitters or environmen-
tal stimulants to the intracellular metabolic pathways [9]. Their 
structure consists of seven transmembrane-spanning helices 
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AbSTR AcT
Primary aldosteronism (PA) is the most common form of en-
docrine hypertension. Agonistic autoantibodies against the 
angiotensin II type 1 receptor (AT1R-Abs) have been described 
in transplantation medicine and women with pre-eclampsia 
and more recently in patients with PA. Any functional role of 
AT1R-Abs in either of the two main subtypes of PA (aldoster-
one-producing adenoma or bilateral adrenal hyperplasia) re-
quires clarification. In this review, we discuss the studies per-
formed to date on AT1R-Abs in PA.
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bound by intra- and extracellular loops [11]. On the extracellular 
side, GPCRs are targeted by their ligands but also by autoantibod-
ies, which may induce agonistic receptor stimulation or inhibition 
dependent on the autoantibody binding site to the first and sec-
ond or third extracellular loops, respectively [9].
Binding of extracellular agonists activate the receptor by initi-
ating a conformational change that induce further signal transduc-
tion pathways [12]. Conformational changes result in the hete-
ro-trimeric G-protein to exchange GDP for GTP at its Gα subunit 
[13]. The Gα subunit with GTP and the Gβγ subunit both dissociate 
from the receptor, resulting in the activation of specific signaling 
pathways such as, adenylyl cyclase (via cAMP generation) and phos-
pholipase C [via diacylglycerol (DAG) and inositol trisphosphate 
(IP3) production] [13]. The Gα subunit bound to GTP hydrolyses 
GTP back to GDP to reassociate with the Gβγ subunit [13]. Recep-
tor signaling determination is mediated by G-protein-coupled re-
ceptor kinases (GRK) which phosphorylate the activated receptor 
to bind to a distinct scaffold protein for subsequent internalization 
into the cells [13]. These scaffold proteins are arrestins and are 
known to desensitize GPCRs and induce G-protein independent 
signaling [14]. Following internalization the receptor is either de-
graded or recycled back to the plasma membrane [13]. Besides its 
involvement in GPCR internalization, arrestins are able to interact 
directly with activated GPCRs resulting in a clear conformational 
change that could initiate further downstream signaling pathways 
[13]. There is some evidence for biased agonism of GPCRs towards 
β-arrestin-mediated signaling [15, 16].
The angiotensin II type 1 and 2 receptors (AT1R and AT2R) are 
GPCRs with opposing functions in blood pressure regulation and 
sodium excretion [17–19]. The two subtypes share 34 % sequence 
homology and stimulate different signaling pathways to elicit dis-
tinct and counter-regulatory biological functions [17]. AT2R is high-
ly expressed in the fetal state although lower levels are present in 
the adult brain, heart, kidney and the adrenal [17]. In some diseas-
es, AT2R is upregulated acting as an anti-inflammatory and repair-
ing factor for wound healing or after cardiac or vascular events 
[20, 21]. In contrast, the AT1R is widely distributed, for example, in 
the adrenal gland, liver, kidney, fat, brain, placenta, spleen, or thy-
roid, and its physiological role as a component of the renin-angio-
tensin-aldosterone system (RAAS) is well characterized via binding 
of its cognate ligand angiotensin II for blood pressure regulation, 
vasoconstriction, inflammatory response and vascular and cardiac 
hypertrophy [21].
The Discovery of Autoantibodies Against Angiotensin 
II Type 1 Receptor
The prevalence of autoimmune diseases in the population is around 
2.5 % although autoantibodies are also often present in healthy in-
dividuals [22, 23]. Impaired B cell tolerance can allow autoanti-
body-producing B cells with medium or low binding affinity to 
self-antigens to escape from elimination or further anergy during 
B cell maturation thus becoming autoantibody-secreting plasma 
cells [22]. However, the pathogenic role of autoantibodies is most-
ly unknown.
The role of autoantibodies against the AT1R (AT1R-Abs) in hy-
pertension has been investigated over the last decades. In 1999, 
Wallukat et al. described the presence of AT1R-Abs in patients with 
preeclampsia, which is discussed further below [24]. This discov-
ery was extended one year later by Fu and coworkers who observed 
elevated AT1R-Ab levels in 33 % patients with malignant secondary 
hypertension, but also found increased levels of AT1R-Abs in 14 % 
of the control group [25]. Soon afterwards, an association of AT1R-
Abs and renal graft failure was observed by many research groups, 
especially in patients without donor-specific human leukocyte an-
tigen (HLA)-antibodies [26–29]. Dragun et al. reported a compa-
rable prevalence of kidney rejections associated with either AT1R-
Abs (3.6 %) or donor-specific HLA-antibodies (3.2 %) in a cohort of 
278 kidney transplantations including 119 rejections [29]. High 
levels of AT1R-Abs ( > 17 units) without additional presence of do-
nor-specific antibodies have been ascribed to an increased risk for 
antibody-mediated kidney rejection [27]. Other studies reported 
on AT1R-Ab levels of  > 9 U/ml or  > 10 U that have been shown to el-
evate the risk of graft loss [28, 30]. Notably, in some patients (17–
47 %) AT1R-Abs were already present before transplantation [26–
28, 30]. A case report of Jobert et al. described a 28-year old male 
recipient of a well-matched renal allograft lacking anti-HLA-anti-
bodies but with a high AT1R-Ab level of 14.1 U/ml prior transplan-
tation who developed acute vascular rejection four days post-trans-
plantation [31]. The authors hypothesized that the AT1R-Abs are 
the only factor that could have led to the allograft rejection due to 
the otherwise well-matched HLA-type and virus status [31]. Treat-
ment with anti-thymocyte globulin, methylprednisolone, cande-
sartan and plasma exchange was successful suggesting probably 
plasma exchange as a considerable option in patients with AT1R-
Abs [31]. However, AT1R-Abs also appeared after kidney transplan-
tation in prior AT1R-Ab-negative patients without an associated 
worse clinical outcome [32]. Of note is that Taniguchi et al. stressed 
that such studies report an association of AT1R-Ab levels and allo-
graft failure and do not explain any causal relationship [26]. The 
occurrence of autoantibodies is widely distributed in transplanta-
tion medicine but also in autoimmune diseases such as Hunting-
ton, multiple sclerosis or systemic sclerosis [33, 34]. A summary of 
diseased states widely reported as associated with increased AT1R-
Ab levels is shown in the ▶Fig. 1.
Comparison of Different Assays for AT1R-Ab 
Characterization
AT1R-Abs in patient serum have been widely measured by en-
zyme-linked immunosorbent assays (ELISA). For such ELISAs, the 
target antigens are immobilized on a solid phase, mainly on a mi-
croplate to detect binding autoantibodies from serum samples 
[22]. As antigens serve the human full-length AT1R or peptides 
comprising known epitopes (AFHYESQ or ENTNIT) for AT1R-Abs in 
the AT1R second extracellular loop [29]. The bound autoantibodies 
are then either directly labelled with reporter enzymes (direct 
ELISA) or by a secondary labelled antibody coupled to a reporter 
enzyme (indirect ELISA) for quantification. Internal laboratory as-
says have been developed as well as commercially available kits 
(▶Table 1). Piazza et al. compared in a study with patients diag-
nosed with APA two of the commercially available Sandwich-ELISA 
kits used for AT1R-Abs determination [35, 36] by CellTrend and Cus-
abio [37]. The results of both assays were consistent and both 
demonstrated higher AT1R-Ab levels in patients diagnosed with an 
APA compared with healthy controls [37]. In contrast, the same 
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CellTrend kit and a second kit from ELISA-Creative Diagnostics re-
vealed the detection of contrasting AT1R-Ab levels depending on 
the assay used for patients with pre-eclampsia relative to controls 
[38]. This highlights the inherent drawbacks of assays based on the 
detection of AT1R-Ab concentrations and not AT1R bioactivity. To 
investigate if AT1R-Abs activate the AT1R, assays have been devel-
oped, which measure cultured spontaneously beating neonatal rat 
cardiomyocytes in response to immunoglobulins G (IgGs) and the 
perfused rat cremaster arteriole assay to measure losartan-sensi-
tive antibody-mediated vasoconstriction [24, 39]. In vitro experi-
ments using genetically engineered cells (for example, Chinese 
hamster ovary cells (CHO), or human bone osteosarcoma cells 
(U2OS)) stably transfected with human AT1R) to measure the func-
tional activation of the AT1R in response to whole serum or purified 
IgGs have also been used [37–40]. Upon receptor activation, the 
transfected U2OS or CHO cells mediate chemiluminescent or fluo-
rescent signals that can be quantitatively measured. Of note is that 
many cell-based assays used to quantify AT1R-Ab agonistic activi-
ty measure responses mediated by the β-arrestin signaling path-
way. In addition, the production of aldosterone or increased ex-
pression of the aldosterone synthase gene (CYP11B2) in response 
to treatment with IgG fractions or whole serum has been measured 
using human adrenocortical carcinoma cell line (HAC15) [37].
AT1R-Abs and Pre-Eclampsia
Pre-eclampsia is the sudden appearance of hypertension in preg-
nant women after 20 weeks’ gestation week that is associated with 
increased risks of long-term hypertension, stroke, cardiovascular 
▶Fig. 1 Potential pathological effects of agonistic AT1R autoantibodies: Autoantibodies to the AT1R have been described in a number of different 
pathological states as indicated. Continuous lines represent a direct effect, dashed lines indicate an indirect effect, dotted lines denote putative 
effects. Figure compiled by the authors using elements of https://smart.servier.com/ (licensed under Creative Commons Attribution 3.0 Unported 
License).
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morbidity and proteinuria for the mother and uteroplacental dys-
function, preterm birth, fetal distress and fetal death for the un-
born child [24, 41]. In 1999, Wallukat et al. were the first who re-
ported the presence of AT1R-Abs in pregnant women with pre-ec-
lampsia compared to controls [24]. The purified IgG fractions from 
patients with preeclampsia demonstrated losartan-suppressible 
AT1R stimulation and identified the amino acid sequence AFHYESQ 
in the secondary extracellular loop of the AT1R as the possible bind-
ing site for these autoantibodies [24]. Peptides against the AFHY-
ESQ epitope successfully abolished AT1R-Ab mediated activation 
of the AT1R suggesting a potential target for the treatment of pa-
tients with pre-eclampsia [42, 43]. Despite postpartum persisting 
AT1R-Ab levels in 17 % of women with previous pre-eclampsia [44], 
the drop in AT1R-Ab levels after giving birth and the correlation of 
AT1R-Ab levels with the severity of the disease indicated a role for 
AT1R-Abs in pre-eclampsia [24, 45]. Numerous studies subsequent-
▶Table 1 Angiotensin II type 1 receptor autoantibody measurements in primary aldosteronism.
ELISA
Indirect ELISA using immobilized AT1R peptides of extracellular loop 2
Rossitto et al. 2013 [51] – AT1R-Ab level in patients with PA (n = 46) higher than in NT (n = 45)
– AT1R-Ab level in patients with APA (n = 26) 2-fold higher than IHA (n = 20)
Kem et al. 2014 [39] – elevated AT1R-Ab levels in 4 of 13 patients with PA (31 %)
Li et al. 2015 [40] – elevated AT1R-Ab levels in 5/12 (42 %) of BAH, 3/13 (23 %) of APA and 1/15 (7 %) of NT
Sandwich-ELISA with full-length AT1R
Sabbadin et al. 2018 [35] Human angiotensin II receptor 1 antibody, ATIIR1 Ab ELISA Kit (Cusabio, Wuhan, China)
– elevated AT1R-Ab titers in PA (n = 44) than in NT (n = 18)
– AT1R-Ab level comparable between APA and BAH
Piazza et al. 2019 [37] Human angiotensin II receptor 1 antibody, ATIIR1 Ab ELISA Kit (Cusabio, Wuhan, China)
– AT1R-Ab levels in patients with APA (n = 12) compared to NT (n = 7)
Piazza et al. 2019 [37] CellTrend, Luckenwalde, Germany
– higher AT1R-Ab levels in patients with APA (n = 27) compared to NT (n = 7)
Williams et al. 2019 [38] CellTrend, Luckenwalde, Germany
– equal levels of AT1R-Abs in APA (n = 40), BAH (n = 40), PH (n = 40), NT (n = 25)
Williams et al. 2019 [38] Creative Diagnostics
– equal levels of AT1R-Abs in APA (n = 40), BAH (n = 40), PH (n = 40), NT (n = 25)
Functional AT1R agonist measurements
cell-based functional assays
Williams et al. 2019 [38] SERUM:
– without losartan: no group differences between APA (n = 40), BAH (n = 40), PH (n = 40), NT (n = 25)
– with losartan: AT1R-bioactivity of APA, PE and NT reduced in comparison to BAH
Purified IgG:
– without losartan: AT1R-bioactivity of BAH higher than of APA; AT1R-bioactivity of BAH, PH, PE all higher than NT
– with losartan: AT1R-bioactivity not abolished by losartan
Kem et al. 2014 [39] SERUM: 
– elevated AT1R-bioactivity through serum from PA patients compared to NT, mainly suppressed by losartan/candesartan
Li et al. 2015 [40] SERUM:
–  15/25 (60 %) of patients with PA showed autoantibody-mediated AT1R-bioactivity: 9/12 (75 %) patients with BAH; 
6/13 patients with APA (46 %)
– NT were negative for AT1R-Ab induced AT1R-bioactivity
– losartan inhibited AT1R-bioactivity
Piazza et al. 2019 [37] SERUM: 
– values below threshold; AT1R-bioactivity from APA patient serum does not differ from NT
Perfused rat cremaster arteriole assay
Kem et al. 2014 [39] SERUM: 
– higher cremaster arteriole contractility in patients with PA (n = 3) than NT which could be inhibited by losartan
cYP11b2-mRNA expression in HAc15 cells
Piazza et al. 2019 [37] Purified IgG:
– purified IgG from patients with an APA (n = 10) induced a 40 % increase in CYP11B2-mRNA expression
Ab: Antibody; APA: Aldosterone producing adenoma; AT1R: Angiotensin II type 1 receptor; BAH: Bilateral adrenal hyperplasia; ELISA: Enzyme-linked 
immunosorbent assay; HAC15: Human adrenocortical cell line; NT: Normotensive controls; PH: Primary hypertension.
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ly supported the findings of Wallukat et al. with reports of AT1R-Abs 
in pregnant women with pre-eclampsia [43, 46, 47]. Diverse stud-
ies have reported a role for AT1R-Abs in pre-eclampsia in mediating 
intracellular Ca2 +  release [43], induction of nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase and reactive oxygen spe-
cies (ROS) production leading to the activation of the transcription 
factor nuclear factor Kappa B (NFκB) activation [46] and initiation 
of vasoconstriction [47], all of which were inhibited by losartan. 
Further in vivo experiments ascribed a causative role for AT1R-Abs 
in the development of pre-eclampsia. Zhou et al. infused pregnant 
mice with human total IgG or affinity purified AT1R-Abs which re-
sulted in the characteristic symptoms of pre-eclampsia including 
proteinuria, hypertension and abnormal appearance of the placen-
ta [42]. In addition, Wenzel et al. injected angiotensin II, purified 
rabbit AT1R-Abs or both in pregnant rats which induced a pheno-
type resembling pre-eclampsia when a combination of both, angi-
otensin II and purified AT1R-Abs were applied [48]. In contrast to 
the aforementioned findings, in a population of Mexican-Mestizo 
women diagnosed with pre-eclampsia no AT1R-Abs were found 
[49]. Despite an apparently clear role for AT1R-Abs in pre-eclamp-
sia, a recent retrospective analysis of 485 women with pre-eclamp-
sia concluded that AT1R-Ab levels alone are not sufficient to predict 
hypertension in such patients, and additional risk factors for hyper-
tension should be considered [50].
AT1R-Abs in Primary Aldosteronism
Recently, AT1R-Abs were also detected in patients diagnosed with 
PA suggesting a possible role of AT1R activation in aldosterone pro-
duction in some patients. Rossitto et al. described for the first time 
AT1R-Abs in patients with PA which was subsequently reported by 
other research groups [39, 40, 51]. In this study, the AT1R-Ab levels 
of serum from 46 patients with PA (26 APA, 20 BAH) as well as 62 
patients with primary hypertension (PH) was measured by an indi-
rect ELISA assay using an immobilized peptide of the second extra-
cellular loop of AT1R. Thirteen pregnant women with preeclampsia 
and 45 normotensive control patients (NT) were used as positive 
and negative controls, respectively. Patients with PA and PH showed 
significantly higher AT1R-Ab levels than NT, with higher levels in pa-
tients with PA than in PH [51]. In 92.3 % of patients with APA, AT1R-
Abs were detected comprising a concentration 2-fold higher than 
of patients diagnosed with BAH or PH, despite comparable blood 
pressure levels (▶Table 1) [51]. Interestingly, the AT1R-Ab levels of 
patients with APA and women with pre-eclampsia were similar 
(3.43 ± 1.20 vs. 3.66 ± 1.79) [51]. Another indirect ELISA using the 
peptide AFHYESQ located in the extracellular loop 2 was performed 
in the studies of Kem et al. and Li et al. [39, 40]. Kem et al. described 
elevated AT1R-Ab levels in 4 of 13 patients with PA (31 %) while the 
latter study focused on the subtypes of PA and measured elevated 
AT1R-Ab levels in 42 % of BAH, 23 % of APA and 7 % of NT which con-
tradicts the initial findings of the same group [40].
Using a commercially available ELISA kit with full-length AT1R as 
antigen, Sabbadin et al. found higher AT1R-Ab levels in patients with 
PA compared with healthy controls which is in accordance with pre-
vious findings [35]. However, the authors could not distinguish pa-
tients with APA (n = 15) and BAH (n = 29) [35]. In contrast, a larger 
study comprising a cohort of 80 patients with PA (40 APA, 40 BAH), 
40 with PH, 23 with pre-eclampsia and 25 NT observed equal lev-
els of AT1R-Abs in all groups except for patients with pre-eclampsia 
using two different commercial available ELISA kits (▶Table 1) [38]. 
Using the same CellTrend ELISA kit, Piazza et al. described higher 
AT1R-Ab levels in patients with APA (n = 27) compared to healthy 
controls (n = 7) [37]. Overall, it is clear that these studies using ELI-
SA-based assays have yielded highly contrasting results.
AT1R-Ab levels pre- and post-adrenalectomy were investigated 
in 14 patients with APA [37] who were biochemically cured follow-
ing surgery according to the PASO criteria [52]. The authors found 
no significant decrease in AT1R-Ab levels at one month after adre-
nalectomy indicating that the resected adrenal was not the source 
of antigens stimulating the immune response [37].
When summarizing the results of AT1R-Ab quantification by 
ELISA it can be stated that there is a high variability in the AT1R-Ab 
levels of patients with PA with studies reporting contrasting AT1R-
Ab levels for the different subtypes of PA [39, 51]. Of note is that 
elevated AT1R-Ab levels were also described in healthy individuals 
without initiating subsequent AT1R activation [40]. Furthermore, 
Kem et al. found for instance more frequently elevated AT1R-bio-
activity in patients with PA by a cell-based assay using AT1R-trans-
fected CHO cells than autoantibodies were quantified by ELISA 
which is in agreement with a second study from the same group 
[39, 40]. The authors hypothesized that the use of a linear peptide 
for the secondary extracellular loop instead of full-length AT1R 
could miss other potential binding sites for the autoantibodies in 
ELISA [39]. This is supported by the findings of multiple binding 
sites for IgG on the AT1R [53] and the recommendations to avoid 
using immobilized peptides in ELISA for GPCR-autoantibody detec-
tion [54]. However, using the full-length AT1R does not guarantee 
the functional activity of the captured autoantibodies which can 
be demonstrated in cell based-functional assays using whole serum 
and/or purified IgG [38–40].
The rat cremaster arteriole assay or AT1R-transfected CHO cells 
both demonstrated elevated receptor activation when exposed to 
serum of patients with PA compared to controls, which was largely 
normalized by the AT1R-blockers losartan or candesartan [39]. Simi-
larly, candesartan was able to reduce AT1R-Ab-stimulated aldoster-
one production in vitro in HAC15 cells [39]. AT1R-activity is more fre-
quently observed in patients diagnosed with BAH (75 %) compared 
to APA patients (46 %), while serum of NT induced no AT1R-bioactiv-
ity [40]. However, one research group failed to measure AT1R-bioac-
tivity in patients with APA and controls using this assay which might 
be due to the lack of activating function of the autoantibodies [37]. 
AT1R-transfected U2OS cells also showed no group differences when 
incubated with serum of patients with APA, BAH or pre-eclampsia or 
NT in the absence of losartan [38]. Notably, the administration of lo-
sartan only barely reduced AT1R-activation in the BAH group in com-
parison to APA, pre-eclampsia and NT indicating a losartan-independ-
ent activation pathway of the receptor [38]. Purified IgGs also caused 
an increase in AT1R-bioactivity in the BAH compared to APA group, 
independent of losartan [38]. This can be explained by different bind-
ing sites for IgG and losartan at the AT1R while angiotensin II and lo-
sartan share a common binding site on the AT1R [53].
Autoantibody levels were not correlated with age, gender, BMI, 
blood pressure, baseline aldosterone and aldosterone-to-renin 
ratio (ARR) [35, 51]. Mineralocorticoid receptor antagonist (MRA) 
treatment of patients with PA was also not associated with AT1R-
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Ab levels [35]. Agonistic AT1R-Abs displayed vasoconstrictive ef-
fects and correlate with the mean arterial pressure [39, 40]. The 
previously mentioned elevated agonistic activity of AT1R-Abs in pa-
tients diagnosed with BAH and the higher responsiveness to angi-
otensin II in those patients [55] suggest an allosteric function of 
the autoantibodies which promotes the binding angiotensin II to 
its receptor. This is supported by the reduction of aldosterone lev-
els after captopril-challenge in AT1R-Ab-positive compared with 
AT1R-Ab-negative patients with hypertension or PA [51]. In addi-
tion, treatment of HAC15 cells with angiotensin II and affinity-pu-
rified IgGs increased aldosterone production compared with angi-
otensin II treatment alone [39].
As previously indicated, upon activation, the AT1R can initiate 
two distinct independent signaling pathways. More prominent is 
the G-protein signaling pathway in which PIP2 is cleaved to DAG and 
IP3 resulting in increased intracellular Ca2 +  and aldosterone pro-
duction [15]. Secondly, biased signaling mediated by β-arrestin1 
is independent of G-proteins and may occur in parallel to the G-pro-
tein signaling pathway [15]. Aldosterone production appears to be 
stimulated via extracellular signal-regulated kinase (ERK)-mediat-
ed activation of steroidogenic acute regulatory protein (StAR) to 
promote transfer of cholesterol to mitochondria [15]. When AT1Rs 
are activated by angiotensin II, both pathways appear to be initiat-
ed [15]. This has been demonstrated in vivo in rats with overexpres-
sion of β-arrestin1, which showed suppressed aldosterone produc-
tion only through the administration of candesartan or valsartan 
and not by losartan or irbesartan despite belonging to the same 
pharmacological class [56, 57].
In conclusion, some evidence supports a pathological role for 
autoantibodies against the AT1R in different diseases. It has not 
been established if AT1R-Abs play a causative role or are a conse-
quence of the pathology. Further studies are warranted to address 
the functional relevance of AT1R-Abs in PA and the significance of 
AT1R biased signaling.
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